Valiltramiprosate - Alzheon
Alternative Names: ALZ 801; BLU-8499; NRM-8499; Tramiprosate prodrug - AlzheonLatest Information Update: 21 Apr 2025
At a glance
- Originator BELLUS Health
- Developer Alzheon; BELLUS Health; National Institute on Aging
- Class Alkanesulfonic acids; Antidementias; Neuroprotectants; Propylamines; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Alzheimer's disease
- Discontinued Cerebral amyloid angiopathy; Down syndrome
Most Recent Events
- 21 Apr 2025 Discontinued - Phase-II for Cerebral amyloid angiopathy (PO) (Alzheon pipeline, April 2025)
- 21 Apr 2025 Discontinued - Phase-II for Down syndrome (PO) (Alzheon pipeline, April 2025)
- 10 Apr 2025 Efficacy and adverse events data from phase-III APOLLOE4 trial in Alzheimer's disease released by Alzheon